Secretase inhibition in Alzheimer's disease therapeutics reveals functional roles of amyloid-beta42.

This is consistent with a recent meta-analysis of nearly 26,000 AD patients across 24 long-term, placebo-controlled anti-Aβ clinical trials, which identified a highly significant positive association between CSF Aβ 42 levels and both cognitive and clinical performance.

also in 132,142 other papers